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Abstract
Stents have become the most successful device to treat advanced atherosclerotic lesions. However, one of the
main issues with these interventions is the development of restenosis. The coating of stents with antiprolifera-
tive substances to reduce this effect is now standard, although such drugs can also delay re-endothelialization of
the intima. The drug release strategy is therefore a key determinant of drug-eluting stent efficacy. Many mathe-
matical models describing drug transport in arteries have developed and, usually separately, models describing
the mechanics of arterial tissue have been devised. However, there the literature is lacking a comprehensive
model that adequately takes into account both the mechanical deformation of the porous arterial wall and the
resulting impact on drug transport properties. In this paper, we provide the most comprehensive study to date
of the effect of stent mechanical expansion on the drug transport properties of a three-layer arterial wall. Our
model incorporates the state-of-the art description of the mechanical properties of arterial tissue though an
anisotropic, hyperelastic material model and includes a nonlinear saturable binding model to describe drug
transport in the arterial wall. We establish relationships between mechanical force generated through device
expansion and alteration in diffusion within the arterial wall and perform simulations to elucidate the impact
of such alterations in spatio-temporal drug release and tissue uptake. Mechanical deformation of the arterial
wall results in modified drug transport properties and tissue drug concentrations, highlighting the importance
of coupling solid mechanics with drug transport.
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1 Introduction
Coronary heart disease (CHD) is the leading cause of death worldwide [1]. CHD is attributed to
atherosclerosis, the hardening and narrowing of the arterial lumen due to the build-up of cholesterol
and fatty deposits on the inner wall of the vessel. This in turn reduces blood flow through the coronary
arteries to the heart muscle.
Stent implantation has become the most succesful strategy in the treatment of CHD by percuta-
neous coronary intervention (PCI). However, in-stent restenosis (ISR), a gradual luminal re-narrowing
mainly due to the vessel wall injury induced by the device, is the major clinical limitation of this tech-
nique [2]. The introduction of drug-eluting stents (DES), which release antiproliferative substances
into the arterial tissue has contributed to the dramatic reduction in incidence of ISR to less than
10% [3]. However, the risk of developing late or very-late stent thrombosis (ST) is typically higher
with the use of DES compared with bare-metal stents, and given the high mortality rates associated
with ST, this issue remains an important safety concern that needs to be addressed [2, 4].
The use of computational (in silico) modelling and simulation for coronary stents has emerged as
a powerful technique that can contribute to addressing some of the limitations of often difficult and
expensive experimental analysis [5,6]. In terms of simulating the deployment of a stent inside a coro-
nary artery, these models can provide useful insights into the stress-strain response that the device
induces within the arterial tissue and how stent design factors contribute to mechanical performance
in vivo. In the literature, several in silico studies with different levels of complexity have been per-
formed to investigate geometrical and material properties of stents, different deployment strategies,
effects of arterial curvature, the use of patient-specific geometries and the inclusion of stenosis and
atherosclerotic tissue [5, 7–12]. However, these models do not adequately account for drug-transfer
from a DES.
In the context of drug transport modelling, computational analysis can contribute to a better under-
standing of drug-release and binding mechanisms in arteries, aiming to guide the development of a
next generation of DES with more favourable safety and efficacy [13]. A large number of computa-
tional studies have been developed in the last decade for this purpose, adopting either well-defined
one-dimensional simplifications [6, 14–20], or two-dimensional [21–31] and three-dimensional for-
mulations [32–35]. These models generally consider an intact vessel with diffusion, advection and
binding dictating the transport of drugs within the blood flow and the respective wall layers. How-
ever, these models do not take account of the influence of mechanical deformation on drug transport.
In terms of modelling the drug binding process in the arterial wall, a nonlinear saturable reversible
binding model is currently the well-accepted approach [15, 25, 28]. The precise form of modelling
binding is controversial, however, with some authors highlighting the importance of taking into ac-
count binding to specific receptors and binding to non-specific sites (general extracellular matrix sites)
as two separate phases [6,36]. In terms of modelling drug dynamics within the stent coating, although
most models assume that drug transport is governed purely by diffusion [24,25,28], depending on the
physical and chemical characteristics of the polymeric coating and of the drug, it may be necessary to
also account for other phenomena such as dissolution [6,19], degradation [29,31,37] or erosion [37].
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There are a limited number of studies that attempt to incorporate both the mechanics of arterial tissue
and drug transport. For example, in their 3D models, Migliavacca et al. [32] and Cutrı̀ et al. [35]
include drug transport in an arterial wall deformed by their simulations of stent deployment, but
neither model relates the drug transport parameters to the level of deformation. Ferreira et al. [29,
31] use a linear viscoelastic model to explore how drug diffusion may be hindered in the presence
of atherosclerotic plaque, but do not account for mechanical deformation of the arterial wall as a
result of stent deployment. Feenstra and Taylor [34], through a porohyperelastic-transport approach,
calculate the geometry, porosity field and interstitial fluid velocity directly from a simulation of stent
deployment and use these within a model of drug transport in the arterial wall consisting of three
distinct layers. In this sense, tissue porosity and the contribution to drug transport of advection are not
assumed a priori. However, this model assumes a linear drug reaction and drug diffusion coefficients
that do not vary with deformation. Denny et al. [26, 27] do model the influence of strut compression
on local diffusivity [26, 27] through simulations of the compression of an idealised arterial wall by
an idealised unit cell model of a stent, but their model does not adequately account for the effects of
nonlinear binding of drug.
In this paper, we provide the most comprehensive study to date of the effect of stent mechanical ex-
pansion on the drug transport properties of a three-layer arterial wall. Our model incorporates the
state-of-the art description of the mechanical properties of arterial tissue through an anisotropic, hy-
perelastic material model and includes a nonlinear saturable binding model to describe drug transport
in the arterial wall. We establish relationships between mechanical force generated through device
expansion and alteration in diffusion within the arterial wall and perform simulations to elucidate the
impact of such alterations in spatio-temporal drug release and tissue uptake.
1.1 Outline
We start with a discussion of the mechanical aspect of the problem and present the material models
employed to describe the stent-induced deformation of arterial tissue. We then derive expressions for
the arterial drug diffusion coefficients as a function of deformation (Section 2.2). This is followed
by a description of the drug transport model in the lumen, where blood flow is described by the
steady Navier-Stokes equations, and in the multi-layer anisotropic porous tissue of the arterial wall,
where Darcy’s law is used to calculate the plasma filtration through the tissue and advection-diffusion-
reaction equations are used to model the drug dynamics (Section 2.3). A detailed description of the
computational geometry and the implementation of the model equations is provided in Section 2.4.
The key results are presented in Section 3, along with a discussion of their significance. Finally, in
Section 4 and 5 we reiterate the limitations of our work and provide some final conclusions, respec-
tively.
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2 Material and Methods
2.1 Mechanical model
2.1.1 Modelling the arterial wall
We consider the arterial wall to be composed of three distinct layers: the intima, the media and the
adventitia. Each individual layer is modelled as an anisotropic, hyperelastic and incompressible ma-
terial [38, 39] and reinforced by two families of collagen fibres, following the model proposed by
Gasser et al. [40]. In this model, the strain-energy function (SEF) is given by:













where I1 = tr(C) represents the first invariant of the right Cauchy-Green deformation tensor [41],
C, characterizing the isotropic mechanical response of the elastin [42, 43] while I4 ≥ 1 and I6 ≥ 1
characterize the mechanical response in the preferential directions of the fibers/cells [39]. The material
parameters µ > 0 and k1 > 0 have the dimension of stress whereas k2 > 0 and 0 ≤ κ ≤ 1/3, that
characterizes the level of dispersion of the collagen orientations, are dimensionless. When κ = 0 the
fibres are perfectly aligned (no dispersion) and when κ = 1/3 the fibres are randomly distributed and
the material becomes isotropic. Assuming that the anisotropy directions are helically oriented at ±β
degrees with respect to the longitudinal direction, the invariants I4 and I6 can also be expressed as a
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where β1 = β and β2 = −β [44]. Moreover, it has been assumed that the strain energy correspond-
ing to the anisotropic terms only contributes to the global mechanical response of the tissue when
stretched, that is I4 > 1 and I6 > 1, and that the tissue does not bear any load when compressed.
The model parameters were calibrated against the experimental data reported by Holzapfel et al. [39]
and shown in Table 1. Notice that all tissues have been considered as incompressible for this material
parameter identification, i.e. with volume ratio J = det F = 1, where F is the deformation gradient
tensor.
2.1.2 Modelling stent struts and stent coating
The stent struts are modelled as an elasto-plastic material with a Young’s modulus, E, of 200 GPa
and Poisson’s ratio, ν, of 0.28, representative of biomedical grade stainless steel alloy 316L [5]. The
plasticity is described by isotropic hardening J2 flow theory with the tensile stress-strain curves taken
from the literature [45], including a yield strength, σy, of 264 MPa and a ultimate tensile strength
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(UTS), σu, of 584 MPa at an engineering plastic strain of 0.247. The stent coating is modelled as a
nonlinear elastic material with bilinear behaviour simulating a phosphorylcholine (PC)-based polymer
coating with a Young’s modulus of 240 MPa, a Poisson’s ratio of 0.5, a yield strength of 16 MPa and
a tangent modulus, Et, of 7.7 MPa [46, 47].
[Table 1 about here.]
2.2 Derivation of arterial diffusion coefficients as a function of deformation
In a porous media, as in the case of the arterial wall, diffusion of species takes place over a tortu-
ous path that depends on the material structure [48]. The influence of the porosity coupled with the
tortuous nature of the arterial tissue results in the so-called effective diffusivity or effective diffusion





where φ is the porosity, τ represents the tortuosity and Dfree is the species free diffusivity which is





where T is the absolute temperature, kB is the Boltzmann’s constant, µ is the dynamic viscosity
of the solvent (plasma) and R is the hydrodynamic solute (drug) radius. Due to the heterogeneous
structure of the arterial wall, the effective diffusion coefficient will be different for each layer of the
tissue [50]. Moreover, there is experimental evidence to suggest that diffusion within each layer is
anisotropic [51,52]. Tortuosity can be estimated by the ratio between the average pore path length, L,
to the straight distance between the ends of the pore path, X , as: τ = L/X [50]. Although the pore
pathways in the arterial tissue runs through different 3D planes, since we consider a 2D axisymmetric
model in this work, we consider diffusion in the radial and longitudinal directions only. It is assumed
that after stent implantation the arterial wall is radially compressed by the stent struts, leading to
changes in tortuosity, and therefore in arterial diffusivity, in both radial and longitudinal directions
[27, 53]. Fig. 1 shows how stenting theoretically affects the tortuous path in both directions. The
stent expansion will also cause local changes to porosity in the arterial tissue. However, these local
variations are not taken into account in the analysis framework presented assuming that the overall
porosity in each layer is constant. In the radial direction, a variation in the thickness of each layer of






where the subscript i = {ses,m, a} denotes the subendothelial space of the intima, the media and the
adventitia, respectively; the subscript r denotes the radial direction; Li,r is the length of the pore path
in each layer, which is assumed to remain constant [50] and; ∆Xi represents the change in each wall
layer thickness and is positive for an increase but negative for a decrease in thickness. The definition
of radial strain, εi,r = ∆Xi/Xi, is used to relate the tortuosity after compression in the radial direction






= 1 + εi,r, (6)
By relating Eqs. (3) and (6), we can establish a ratio between the initial effective diffusion coefficient,







Following the same reasoning, we can obtain a relationship between the initial effective diffusivity
in the uncompressed wall longitudinal direction, D0i,z, and the effective diffusivity after compression
in that direction, Di,z, through the longitudinal strain, εi,z, and finally define an anisotropic diffusion





D0i,r(1 + εi,r) 0
0 D0i,z(1 + εi,z)
 , (8)
where the subscript z refers to the longitudinal direction. Due to stenting, the arterial wall experiences
compressive strain (εi,r < 0) in the radial direction and tensile strain (εi,z > 0) in the longitudinal
direction, therefore, Eq. (8) shows that the magnitude of the effective diffusivity in the tissue after
stent deployment is lower than the uncompressed value in the radial direction and higher than the un-
compressed value in the longitudinal one. This assumption is in agreement with the experimental data
reported in Levin et al. [52], where it is shown that the radial diffusivity of paclitaxel and sirolimus in
the arterial wall in the radial direction is lower than in circumferential and longitudinal directions.
[Fig. 1 about here.]
2.3 Drug transport model
2.3.1 Modelling blood flow
The blood flow is modelled as a Newtonian fluid and assumed to be steady, laminar and incompress-
ible, described by the stationary Navier-Stokes equations and the continuity equation:
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ρb(ul · ∇)ul = −∇pl + µb∇2ul, (9)
∇ · ul = 0, (10)
where ul is the lumen velocity vector, pl is the pressure in the lumen, µb is the blood dynamic viscosity










where wl,inlet denotes the longitudinal component of the blood velocity in the lumen at the inlet, u0
is the mean blood velocity computed considering a Reynolds number of Rel = 400 [54], rl is the
internal radius of the artery at the inlet (unstented region) and r is the radial coordinate. At the outlet
of the lumen, Γl,outlet, a pressure value of 100 mmHg (13.3 kPa) is fixed [55]. Moreover, a no-slip
boundary condition (wl = 0) was considered at the lumen-arterial wall interface, Γet. In this work,
the pulsatile nature of the blood flow is neglected in agreement with previous models [22–25].
2.3.2 Modelling the porous media
The coronary artery wall consists of three porous layers and the transmural velocity vector field in
each layer, ui, is computed by Darcy’s law, constrained with the solenoidal condition on ui arising




∇pi, ∇ · ui = 0 (12)
where the subscript i = {ses,m, a} denotes the subendothelial space of the intima, the media or the
adventitia, respectively; κi is the Darcian permeability of each layer of the arterial wall; µp is the
dynamic viscosity of the blood plasma and; pi is the pressure within each layer of the tissue. Finally,
to mathematically model the fluid volume flux, Jv, across the semipermeable membranes between
layers, we used the well-known Kedem-Katchalsky equations [56]:
Jv,j = Lp,j(∆pj − ςd,j∆πj), (13)
where the subscript j = {et, iel, eel} denotes the endothelium, the internal or the external elastic lam-
ina, respectively; Lp,j is the hydraulic conductivity of each membrane considered; ∆pj is the pressure
difference across the semipermeable membrane; ςd,j is the Staverman osmotic reflection coefficient
and; ∆πj is the osmotic pressure differential across the membranes. Neglecting the contribution due
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to osmosis [25, 54], we can formulate the flux Jv for each membrane considered:
Jv,et = Lp,et∆pet = Lp,et(pl − pses), (14)
Jv,iel = Lp,iel∆piel = Lp,iel(pses − pm) (15)
and
Jv,eel = Lp,eel∆peel = Lp,eel(pm − pa). (16)
In this work, it is assumed that the endothelium is completely denuded due to stent placement in
regions between struts and upstream and downstream of the stent over a distance that is one half of
the interstrut spacing, measured from the stent strut centers [25, 28]. Outside of these regions the en-
dothelium is assumed to be intact. In denuded regions, the flux Jv,et simplifies to continuity of pressure
(pl = pses). A zero-flow condition, −ni · ui = 0, where ni is the unit outward normal vector to the
corresponding exterior boundary, is imposed to the left and right wall boundaries, Γi,inlet and Γi,outlet,
respectively (sufficiently far from the therapeutic domain so that these boundary conditions have no
effect on the results). At the perivascular side (outer boundary of the arterial wall, Γa), a pressure of
30 mmHg [55] is applied in order to impose a pressure gradient of 70 mmHg [57] between the inner
and the outer surface of the tissue. We refer the reader to Fig. 2 for a diagrammatic representation of
the boundary conditions.
2.3.3 Modelling drug transport within the stent coating
We consider durable polymer-coated stents and assume that drug release is governed by diffusion:
∂cc
∂t
= ∇ · (Dc∇cc), (17)
where cc(r, z, t) is the concentration of dissolved (free) drug in the coating and Dc is the effective
diffusion coefficient of the drug through the porous polymer. We assume that initially all the drug
exists in dissolved form in the polymer coating at concentration C0, calculated as M0/Vc, where
M0 is the initial mass of drug within the coating and Vc is the volume of the coating. Continuity of
concentration and flux, Js,c, of free drug across the outer boundary of the polymeric stent coating is
prescribed:
Js,c = (−Dc∇cc) · nc = −(−Dk∇ck + ukck) · nk, cc = ck, (18)
where the subscript k = {l, ses,m} represents the lumen, the SES and the media, respectively. Fi-
nally, a zero-flux condition, −nc · (−Dc∇cc) = 0 is imposed at the interface between the metallic
strut and the polymer coating.
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2.3.4 Modelling drug transport within the lumen and the arterial wall
Drug transport in the lumen is described by the unsteady advection-diffusion equation:
∂cl
∂t
+ ul · ∇cl = ∇ · (Dl∇cl), (19)
where cl(r, z, t) is the concentration of drug in the lumen, Dl is the diffusion coefficient and ul is
the velocity of the blood flow in the lumen computed by the steady Navier-Stokes equations. The












ua · ∇ca = ∇ · (Da∇ca), (21)












= koncm(bmax − bm)− koffbm, (23)
where ci(r, z, t) denotes the volume-averaged concentration of free drug in layer i, γi ≤ 1 is the
hindrance coefficient, φi is the porosity, ui is the transmural velocity in the porous layers computed
by Darcy’s law and Di is the diffusion tensor in each layer of the arterial wall. For the media layer, we
consider a non-linear saturable reversible binding model (Eq. 23) to describe drug interactions with
the tissue [15,25,58,59]. This model allows one to define two different states of the drug in the media
layer: drug dissolved in the plasma (free drug, cm(r, z, t)) and drug bound to binding sites, bm(r, z, t).
The parameters kon and koff are the association (binding) and dissociation (unbinding) rate constants,
respectively, and bmax is the maximum density of binding sites. The rate constants are related through
the equilibrium dissociation constant, Kd, which is defined as Kd = koff/kon.
The discontinuity of solute flux, Js, across the endothelium and internal and external elastic laminae
is governed by the Kedem-Katchalsky equations:
Js,j = Pj∆cj + sj c̄jJv,j (24)
where Pj is the permeability of each semipermeable membrane, ∆cj is the solute concentration dif-
ferential, sj is the sieving coefficient and c̄j is computed as the weighted average of the concentrations
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setJv,et
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sielJv,iel
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(cm + cadv) +
seelJv,eel
12Peel
(cm − cadv). (27)
Zero drug concentration, cl = 0, and outflow, −nl · (−Dl∇cl) = 0, conditions are imposed at the
inlet and outlet boundaries in the lumen, respectively. Following Vairo et al. [24], the upstream and
downstream boundaries of the tissue are subjected to a zero-flux condition:−ni · (−Di∇ci+uici) =
0. Finally, a perfect sink condition, ca = 0, was applied at the perivascular wall for the free drug.
All governing equations and boundary conditions involved in the computational model have been
summarised in Fig. 2.
[Fig. 2 about here.]
2.3.5 Drug transport model parameters
The majority of DES to date have contained either the drug paclitaxel, sirolimus or a sirolimus ana-
logue. Sirolimus and analogues are anti-proliferative compounds that target the FK-binding protein
12 (FKBP12). This complex subsequently binds to the mammalian target of rapamycin (mTOR) and
thereby interrupts the cell cycle in the G1-S phase. Paclitaxel is also an anti-proliferative compound;
however, it inhibits neointimal growth by binding with and stabilising microtubules, resulting in cell-
cycle arrest in the G0-G1 and G2-M phases [61]. In this work we consider both sirolimus and pacli-
taxel. Wherever possible, the model input parameters for sirolimus and paclitaxel are derived from
experimental data available in the literature and are summarised in Table 2.
[Table 2 about here.]
2.4 Computational model
To analyse the effect of the mechanical expansion of DES on drug transport, an idealised numerical
model is developed that accounts for the changes in the tortuosity of the arterial wall as a result of
strut compression.
2.4.1 Model geometry
We consider initially a 2D-axisymmetric geometry of an idealised straight segment of a coronary
artery where a DES is implanted (Fig. 3a). This geometry is similar to that introduced by Mongrain
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et al. [22] and subsequently used by Vairo et al. [24] and Bozsak et al. [25]. The arterial wall is mod-
elled as a three-layered structure with the subendothelial space (SES) of the intima, the media and the
adventitia defined as different domains (Ωses, Ωm and Ωa, respectively), while the endothelium (ET),
internal elastic lamina (IEL) and external elastic lamina (EEL) are treated as interfacial semiperme-
able membranes (Γet, Γiel and Γeel, respectively). The lumen radius, rl, and the thickness of each layer
of the tissue prior to stent expansion, δi, are listed in Table 3. The DES is represented by 10 polymer-
coated metallic circular struts each of 0.25 mm total diameter, including a coating thickness, δp, of 50
µm, and separated by a centre-to-centre distance of 0.7 mm. A half-embedment configuration of the
stent struts into the arterial is taken into account.
[Table 3 about here.]
[Fig. 3 about here.]
2.4.2 Numerical methods
The commercially available software COMSOL Multiphysics 5.3a (COMSOL AB, Burlington, MA,
USA) was used to create the finite element (FE) mesh and to numerically solve the coupled stent
expansion/drug transport model detailed in Section 2. Three consecutive modelling steps were per-
formed: (1) a stationary mechanical analysis was run in order to simulate the stent deployment, (2)
starting from the deformed geometry computed in (1), a stationary analysis of blood flow dynam-
ics and plasma filtration was carried out, and finally (3) a time-dependent drug transfer analysis was
performed, which was coupled with the data calculated in previous steps such as the strain response
of the vessel wall and the luminal and transmural flow. A sensitivity analysis was previously done
in order to investigate the influence of the mesh and time step size on the results (data not shown).
Different tests were made and mesh and time step independence was assumed when there was less
than 1% difference in the temporal evolution of the total drug content in the media layer of the arte-
rial wall for successive mesh and time step refinements. The computational domains were spatially
discretized using a combination of triangular and quadrilateral elements, resulting in an overall mixed
mesh with approximately 350,000 elements. Lagrange P3-P2 elements were used to discretize the
blood dynamics problem and quadratic Lagrange elements were use to numerically approximate the
mechanical, porous media and drug transport problems. A direct linear solver (MUMPS) was used to
solve the stationary problems with a tolerance for the relative error of the solution of 10-3. The back-
ward differentiation formula (BDF) method was the implicit method used for the time discretization
of the transient drug transport problem, with variable order of accuracy varying from one (also known
as the backward Euler method) to five in order to obtain better stability and variable time step size.
The maximum time-step size was restricted to 1 hour. The relative and absolute tolerances were set
to 10-3 and 10-4, respectively. The resulting system of time-dependent partial differential equations
(PDEs) were solved using a direct linear solver (PARDISO) with a nested dissection preordering al-
gorithm. The computation time of the total simulation (the three steps described in Section 2.4.2) for
each expansion case performed on 8 cores of an Intel® CoreTM i7-4770 CPU @ 3.40 GHz processor
is about 6 hours.
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3 Results and Discussion
In what follows, we will consider results related to five different cases: (i) uncoupled (ii) 0% expansion
(iii) 10% expansion (iv) 20% expansion and (v) 30% expansion, as summarised in Table 4. In each
case, the initial drug loading in the stent coating is fixed to 150 µg. In the uncoupled case, we consider
a straight unpressurised arterial geometry: this is essentially an extension of the model of Bozsak et al.
[25] that now includes the adventitia layer. In the 0 % expansion model the artery is now pressurised,
causing a reduction in thickness of the arterial tissue, but overexpansion of the vessel caused by
the stent is not considered. The remaining cases simulate a pressurised artery as well as a further
deformation over the stented portion due to expansion of the stent. With the exception of case (i), all
of our simulations result in changes to drug transport parameters as outlined in Section 2.
[Table 4 about here.]
In order to compare results between the different cases, we will consider the temporal profiles of drug
content and spatial profiles of local drug concentration in tissue. The total drug content in each layer






(ci + bi) dVi, (28)
where Vi is the volume of layer i, that falls within the therapeutic domain considering a < z < b, with
the origin of the computational geometry placed between the two central struts and with a = −7.5ws
and b = 7.5ws, where ws is the interstrut distance (see Fig. 3); MWdrug is the molecular weight of
the drug (sirolimus or paclitaxel) and; ρi is the density of wet arterial layer tissue. In the absence of
experimental data on a layer-specific basis, we assume a constant density across the three arterial wall
layers (see Table 2). Moreover, since binding site saturation has been linked with efficacy [20,36] we
further calculate the % of binding sites that are saturated as a function of time:






Note that in this model, binding is only considered in the media layer, therefore the % saturation in
the SES and in the adventitia will be zero.
In Fig. 4 we plot temporal profiles of drug content (DC) of two drugs, sirolimus or paclitaxel, within
each layer of the arterial wall for cases (i)-(v). The plots show that, in the media and the adventitia, the
peak DC decreases with stent expansion, however in the SES, the peak DC increases with the level
of expansion. The time that the peak DC occurs increases sequentially moving from the SES to the
adventitia and there is a short delay before drug enters the adventitia, consistent with the time taken
for drug to traverse the media. Similar trends are observed between sirolimus and paclitaxel, although
the values of DC differ as a result of drug-specific binding and transport parameters. Interestingly, the
DC of sirolimus is higher than paclitaxel in the SES and media, but lower in the adventitia.
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In Fig. 5 we separate-out free DC from bound DC in the media for each drug. We observe that, for
each drug, the peak free DC decreases with level of expansion while there is a negligible effect on
peak bound DC. The implication is that expansion has a more pronounced effect on media free drug
concentrations. High levels of binding site saturation are achieved for both sirolimus (≈ 70 %) and
paclitaxel (≈ 75-80 %) rapidly, before a steady decline in saturation levels with time. The decline is
more rapid for paclitaxel. Figs. 4-5 demonstrate that the effect of stent expansion on drug transport in
the arterial wall is dependent not only on the specific layer in question, but also on the particular drug.
Generally speaking, the effect of expansion is more prominent in the case of paclitaxel, particularly
so in the adventitia layer of the arterial wall.
[Fig. 4 about here.]
[Fig. 5 about here.]
While DC provides a useful gross measure to effect comparisons, it is also important to consider the
impact of local drug concentrations, which are linked to the biological effect of the drug, in order to
assess whether drug concentrations locally are at therapeutic (and not toxic) levels. The study of local
drug concentrations is also relevant for the design of effective drug delivery modalities [62]. In Fig.
6 we display spatially-varying profiles of total (free plus bound) local sirolimus concentration in the
arterial wall, calculated as (ci + bi)
MWdrug
ρi
, at four different times across a radial section between the
middle struts (i.e. between the 5th and 6th struts). The greatest differences between the four cases
are observed at early times, where the peak sirolimus local concentration decreases with level of
expansion. When the drug reaches the media/adventitia boundary, there is a sharp jump in the spatial
profiles resulting from the contrast in material properties between the layers, described through the
Kedem-Katchalsky equations. As time progresses, the higher drug retention in the media layer is
evident compared with the adventitia. Our model also enables us to generate 2D plots of local drug
concentration.
In Fig. 7 we show the spatial distribution of the total local concentration of sirolimus in the therapeutic
domain at various time points across 7 days for the 0% and 30% expansion cases. The five time points
after stent implantation shown are: t = 10 min, t = 1 hour, t = 4 hours, t = 24 hours and t = 7 days.
We observe that at early times the concentration is higher close to the stent struts and relatively lower
close to the lumen between struts. After 1 hour of the stent implantation, the plots show the drug
progression through the media layer with time and after 4 hours the concentration distribution pattern
in the arterial wall is more homogeneous. After 1 day, the concentration level of drug in the tissue has
already dropped approximately by an order of magnitude in the media and is almost 40 times lower
in the adventitia compared to the maximum concentration reached in this layer. After a week, the
concentration level in the media is approximately 20 times lower than the maximum concentration
value. In general, similar trends are observed for both cases of expansion, but with lower levels of
concentration when expansion increases. A comparison between the spatial distribution in the tissue
of sirolimus and paclitaxel for each expansion case and the corresponding tables with the maximum
values at each time point may be found in the supplementary material.
[Fig. 6 about here.]
[Fig. 7 about here.]
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In Figs. 8, 9 and 10 we separate-out the free and bound local sirolimus concentration. From these
plots we deduce that, in the early stages, the total local drug concentration profiles are characterized
by rapid infiltration of drug into the SES followed by rapid diffusion into the media (these early pro-
files are governed by the free local drug concentration). However, as time progresses, the total local
drug concentration profiles are dominated by the bound local drug concentration. There is little dif-
ference between binding site saturation levels as we increase level of expansion. However, at early
times, expansion has the effect of leading to binding site saturation deeper into the wall. In order to
probe this further, in Figs. 11 and 12 we present plots showing how the radial and longitudinal diffu-
sion coefficients (Dr and Dz, respectively), magnitude of the radial component of flow (ur) and radial
Peclet number (Per = urδm/Dr) vary across the media layer for the various levels of expansion con-
sidered. Fig. 11a confirms that as we increase the level of expansion, we decrease the radial diffusion
coefficient, with differences greater closer to the intima. The dependence of the longitudinal diffu-
sion coefficient on expansion is more complex, increasing with expansion close to the intima before
decreasing with expansion close to the adventitia as can be seen in Fig. 11b. The level of expansion
also has an influence on the resulting flow-field in the tissue (Fig. 12a): higher radial flow speed is
observed with increasing levels of expansion. When we consider the radial Peclet number (Fig. 12b)
we observe a similar profile to that of radial flow speed (Fig. 12a), confirming that transport across
the wall, in all cases, is dominated by advection. Therefore, despite the relatively modest reduction in
radial diffusion coefficient with expansion, it is primarily advection driven by the pressure gradient
across the wall that governs radial drug transport. These findings support the relatively modest varia-
tion in temporal and spatial profiles of content of drug in Figs. 4-10. Importantly, we note that given
the low value of the radial Peclet number (of order 1), a relatively small change to the flow field could
tip the balance back in favour of diffusion, and in this case the observed changes in drug diffusion as
a result of mechanical expansion will be of more significance. Similar trends are observed for pacli-
taxel, but with greater differences between cases (i)-(v). The corresponding plots for paclitaxel may
be found in the supplementary material.
[Fig. 8 about here.]
[Fig. 9 about here.]
[Fig. 10 about here.]
[Fig. 11 about here.]
[Fig. 12 about here.]
4 Limitations
We would like to emphasize that there are a number of limitations in this work, as we now discuss.
Regarding the geometry of the model, a 2D axysymmetric geometry corresponding to an idealised
representation of a straight segment of a healthy coronary artery has been considered in this study.
This could be improved using more realistic geometries of arteries (curved segments, bifurcations
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or directly 3D patient-specific geometries obtained from medical images) and devices (i.e. complex
geometries of commercial DES). However, such models considerably increase the computational cost
of the simulations and detract from the key objective which was to study the effect of coupling
mechanics-drug transport. Moreover, there is growing evidence that disease composition may well
have an impact on drug release and subsequent tissue distribution [63], however in line with most
of the computational models of drug transport in arteries published in the literature, we neglect the
existence of atheroma plaque in this work.
The large number of parameters involved in the model were obtained from existing experimental data
or other computaional models. These data are taken from different species and may not be represen-
tative of the corresponding parameters in human tissue. Moreover, there is a lack of transport and
reaction parameters for the adventitia layer, therefore these parameters had to be estimated.
Our proposed description of the blood flow (steady Newtonian with inlet Poiseuille velocity profile
and outlet fixed pressure boundary conditions) aligns with the current state of the art model which cou-
ples luminal flow with drug release from stents and tissue binding [25], as well as many other groups
in the field [22–25]. Whilst we accept that in reality we will have pulsatile flow, we point out that the
focus of this study is on drug distribution in arterial tissue, rather than on accurately reproducing flow
patterns in the lumen. We cite evidence from the literature which shows that ’pulsatility contributes
minimally to drug deposition for a well-apposed strut’ [64]. Moreover, the pulsatile flow is charac-
terized by much smaller temporal scales than the temporal scale of the advection-diffusion-reaction
processes which govern drug transport within the arterial wall, therefore, the time dependence mainly
due to the cardiac pulsatile flow was finally neglected in this work.
In terms of modelling drug transport within the stent coating, in line with the vast majority of mod-
els in the literature, simple diffusion model is considered in this work. However, depending on the
particular stent, drug and coating under consideration, more complex nonlinear model that accounts
for the combined effects of diffusion, dissolution and solubility in the polymer coating [19] may be
required in order to describe drug release from the stent. In the literature we can find a wide range for
diffusion coefficients of the drug in the polymeric coating of the stent, representing the range from
fast- to slow-release kinetics. These values range from 10−13 to 10−17 m2·s-1 [25]. Moreover, there are
a large number of stents on the market ranging from durable polymer coated stents, to polymer free
and biodegradable stents and the release kinetics can vary considerably between these different types.
In this work, we assume a typical fast-release stent taking a diffusion coefficient of 10−13 m2·s-1 in all
simulations.
In terms of modelling drug transport within the arterial wall, a single phase nonlinear saturable re-
versible binding model is taken into account. Therefore, in this model we do not take into account
the effect of binding as two separate phases (drug bound to specific receptors and non-specific gen-
eral extracellular matrix sites), the benefits and drawbacks of which are discussed in [6]. In order to
simulate stent deployment, vessel pressurization and displacement have been performed in a single
computation step. A more realistic and challenging approach would be to perform this in two separate
stages.
Finally, we appreciate the importance of validating computational models such as ours against ex-
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perimental data. However, to the best of our knowledge, there is a lack of experimental tests in the
available literature that relate the level of deformation due to stenting, and the consequent modifica-
tion of material properties of the tissue, with the drug content within the arterial wall. We would hope
that this work would inspire the generation of suitable experimental data to validate the work.
5 Conclusions
In this paper, we have provided a comprehensive study of the effect of stent mechanical expansion
on the drug transport properties of a three-layer arterial wall described as an anisotropic, hyperelas-
tic material. We have established relationships between mechanical force generated through device
expansion and alteration in drug diffusion coefficients within the arterial wall and performed simu-
lations to quantify the impact of such alterations in spatio-temporal drug release and tissue uptake.
Our findings demonstrate that mechanical expansion can have an influence on the effective diffusion
coefficients of drugs in arterial tissue, with the overall influence on drug transport through the arterial
wall dependent on the radial Peclet number that is derived from these diffusion coefficients. Since
current computational models typically make use of drug diffusion coefficients that have been de-
rived from static tissue experiments (i.e. not subjected to mechanical expansion), these models are
likely to be under- or over-estimating drug transport and retention in arterial tissue. Finally, we re-
mark that our findings may also be of importance to other forms of localised arterial drug delivery,
such as through drug coated balloons (DCBs). The key difference with DCBs would appear to be a
time-varying dependence on drug transport parameters, coinciding with inflation and deflation of the
balloon.
Acknowledgments: Financial support for this research was provided by the Spanish Ministry of
Economy and Competitiveness through research project DPI2016-76630-C2-1-R and grant number
BES-2014-069737; the Department of Industry and Innovation (Government of Aragon) through the
research group Grant T24-17R (Fondo Social Europeo) and research project LMP121-18 and; the
Instituto de Salud Carlos III (ISCIII) through the CIBER initiative.
References
[1] Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, et al. Global, regional, and
national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global
Burden of Disease Study 2016. The Lancet. 2017;390(10100):1151–1210.
[2] Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. Journal of the
American College of Cardiology. 2014;63(24):2659–2673.
[3] Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review
of clinical data, from pathogenesis to treatment. Journal of Thoracic Disease. 2016;8(10):E1150.
[4] Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we
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Material Model µ (kPa) k1 (kPa) k2 (-) κ (-) β (◦) NRMSE Reference
Intima Gasser et al. [40] 26.16 10485.17 20.00 0.165 50.02 0.0249 fitted to [65]
Media Gasser et al. [40] 1.93 149.10 51.74 0.262 37.47 0.0157 fitted to [65]
Adventitia Gasser et al. [40] 8.17 695.61 604.79 0.265 60.33 0.0298 fitted to [65]
b. STENT STRUTS
Material Model E (MPa) ν (-) σy (MPa) σu (MPa) εu (-) Reference
Stainless steel 316L Elasto-plastic 2·105 0.28 264 584 0.247 [5, 45]
c. STENT COATING
Material Model E (MPa) ν σy (MPa) Et (MPa) Reference
PC-based polymer Bilinear elastic 240 0.5 16 7.7 [46, 47]
Table 1
(a) Material parameters of the Gasser et al. [40] strain energy function (SEF) for the different layers of the
arterial wall. The normalised root mean square error (NRMSE) is a measure of the accuracy of the fit. (b)
Coefficients of the elasto-plastic material model used to describe the behaviour of the stent struts. (c) Values of
the bilinear elasto-plastic model parameters for the phosphorylcholine polymer coating.
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Parameter Description Value Reference
∆p Pressure difference between lumen and adventitia 70 mmHg [57]
Rel Lumenal Reynolds number 400 [54]
ρb Blood density 1060 kg·m-3 [25]
ρp Plasma density 1060 kg·m-3 [25]
µb Blood dynamic viscosity 3.5 · 10−3 Pa·s [66]
µp Plasma dynamic viscosity 7.2 · 10−4 Pa·s [21]
ρi Density of wet arterial tissue 983 kg·m-3 [36]
φses Porosity of the intima 0.983 [55]
φm Porosity of the media 0.258 [55]
φa Porosity of the adventitia 0.85 [18]
γses Hindrance coefficient in the intima 1 Calculated from [25]
γm Hindrance coefficient in the media 0.845 Calculated from [25, 54, 67]
γa Hindrance coefficient in the adventia 1 Estimated
κses Darcy permeability in the intima 2.2·10−16 m2 [55]
κm Darcy permeability in the media 2·10−18 m2 [21]
κa Darcy permeability in the adventitia 2·10−18 m2 [24]
Lp,et Hydraulic conductivity of endothelium 2.2·10−12 m2·s·kg-1 [25]
Lp,iel Hydraulic conductivity of IEL 2.2·10−9 m2·s·kg-1 [25]
Lp,eel Hydraulic conductivity of EEL 2.2·10−9 m2·s·kg-1 Estimated
M0 Drug dose in the coating 150 µg Estimated
Dc Effective diffusion coefficient in the coating 10−13 m2·s-1 [22]
SIROLIMUS
Dl Effective diffusion coefficient in the lumen 4.1·10−12 m2·s-1 [25]
Dses Effective diffusion coefficient in the intima 1.67·10−11 m2·s-1 [25]
Dm,r Effective radial diffusion coefficient in the media 7·10−12 m2·s-1 [52]
Dm,z Effective axial diffusion coefficient in the media 4·10−11 m2·s-1 [52]
Da Effective diffusion coefficient in the adventitia 4·10−12 m2·s-1 Estimated
Pet Permeability of endothelium 3.6·10−6 m·s-1 [25]
Piel Permeability of IEL 9.6·10−6 m·s-1 [25]
Peel Permeability of EEL 9.6·10−6 m·s-1 Estimated
set Sieving coefficient in the endothelium 0.855 [25]
siel Sieving coefficient in the IEL 1 [25]
seel Sieving coefficient in the EEL 1 Estimated
Kd Equilibrium dissociation constant 2.6·10−3 mol·m-3 [15]
kon Drug binding rate constant 2 m3·mol-1·s-1 [15]
koff Drug unbinding rate constant 5.2·10−3 s-1 [6]
bmax Total binding site density 0.366 mol·m-3 [15]
MWsir Molecular weight 914.172 g·mol-1 [52]
PACLITAXEL
Dl Effective diffusion coefficient in the lumen 4.2·10−12 m2·s-1 [25]
Dses Effective diffusion coefficient in the intima 1.7·10−11 m2·s-1 [25]
Dm,r Effective radial diffusion coefficient in the media 2·10−12 m2·s-1 [52]
Dm,z Effective axial diffusion coefficient in the media 5·10−11 m2·s-1 [52]
Da Effective diffusion coefficient in the adventitia 4·10−12 m2·s-1 [24]
Pet Permeability of endothelium 3·10−6 m·s-1 [25]
Piel Permeability of IEL 9.8·10−6 m·s-1 [25]
Peel Permeability of EEL 9.8·10−6 m·s-1 Estimated
set Sieving coefficient in the endothelium 0.86 [25]
siel Sieving coefficient in the IEL 1 [25]
seel Sieving coefficient in the EEL 1 Estimated
Kd Equilibrium dissociation constant 3.1·10−3 mol·m-3 [15]
kon Drug binding rate constant 0.17 m3·mol-1·s-1 Calculated from [15]
koff Drug unbinding rate constant 5.27·10−4 s-1 Calculated from [15]
bmax Total binding site density 0.127 mol·m-3 [15]
MWptx Molecular weight 853.906 g·mol-1 [52]
Table 2
List of parameters related to the drug transport model.
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Parameter Description Value Reference
rl Lumen radius 2.0 mm [68]
δses Intima thickness 0.01 mm [66]
δm Media thickness 0.5 mm [32]
δa Adventitia thickness 0.4 mm [69]
dstrut Strut diameter 0.15 mm [22]
δp Polymeric coating thickness 0.05 mm [22]
ws Interstrut distance 0.7 mm [22]
Table 3
List of parameters related to the geometrical model prior to stent expansion
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Case Description Pressurised artery? Lumen radius in stented region Lumen radius in unstented region
(i) Uncoupled No 2.0 mm 2.0 mm
(ii) 0 % expansion Yes (P=100 mmHg) 2.0 mm 2.0 mm
(iii) 10 % expansion Yes (P=100 mmHg) 2.2 mm 2.0 mm
(iv) 20 % expansion Yes (P=100 mmHg) 2.4 mm 2.0 mm
(v) 30 % expansion Yes (P=100 mmHg) 2.6 mm 2.0 mm
Table 4
Summary of the five different cases considered in the simulations. In each case, the initial drug loading is 150
µg.
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Fig. 1. Schematic showing the influence of stent expansion on tortuosity. (a) Prior to stent expansion, the
tortuous path length in the radial direction through the three layers of the tissue is given by
∑
Li,r, while the
path length in the longitudinal is given by Li,z , where the subscript i = {ses,m, a} denotes the subendothelial
space of the intima, the media and the adventitia, respectively. The total thickness of the wall is given by
∑
Xi.
(b) After stent expansion, the total deformed thickness of the wall is
∑
(Xi + ∆Xi), where ∆Xi > 0 denotes
elongation and ∆Xi < 0 contraction.
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Fig. 2. Schematic showing boundary conditions of the drug transport model.
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Fig. 3. The 3D arterial geometry is assumed to be axisymmetric and therefore a 2D representation is considered
in this work. (a) Overall longitudinal section view of the pre-stressed arterial segment with a DES implanted.
In details a-1 and a-2 a detailed view of the finite element (FE) mesh used in the mechanical model is shown.
(b) Overall longitudinal section view of the arterial segment after stent deployment. In details b-1, b-2 and b-3
a detailed view of the FE mesh used in the drug transport analysis. In both subfigures, the therapeutic domain
(target area for drug transport) considered to compute all the variables of the model is shaded in grey and it was
defined as the domain that extends in a < z < b with the origin of the computational geometry placed between
the two central struts and where a = −7.5ws and b = 7.5ws. In this figure, Ωl defines the vessel lumen, Ωses
the SES, Ωm the media, Ωa the adventitia, Ωs the metallic stent struts and Ωc the stent coating. The boundaries
Γet, Γiel, Γeel define the endothelium, internal and external elastic laminae, respectively; Γa the outer boundary
of the arterial wall; Γcl, Γcses, Γcm and Γcs the interface between the stent coating and blood, SES, media and
metallic strut, respectively; Γl,inlet and Γl,outlet the inlet and outlet boundaries of the lumen, respectively and;
Γi,inlet and Γi,outlet the inlet and outlet boundaries of the wall layers with respect to the blood flow, respectively.27
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Fig. 4. Content of sirolimus (a, c, e) and paclitaxel (b, d, f) in each layer of the arterial wall (presented as µg
drug per g of tissue). In the SES and the adventitia, drug content corresponds exclusively to free drug and in
the media layer corresponds to free plus bound drug. Notice that the scales of the x- and y-axis in (a) and (b)
are different from the rest of the subfigures. The results are shown for the uncoupled model and for luminal
diameter expansions of 0− 30% for the coupled model.
28
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Fig. 5. Content of free sirolimus (a) and paclitaxel (b) in the media layer of the arterial wall (presented as µg
drug per g of tissue). Content of bound of sirolimus (c) and paclitaxel (d) in the media (presented as µg drug
per g of tissue). Binding site % saturation as a function of time for sirolimus (e) and paclitaxel (f) in the media.
Note the different scales on the x- and y-axes. The results are shown for the uncoupled model and for luminal
diameter expansions of 0− 30% for the coupled model.
29


































































































































































































Fig. 6. Spatially varying profiles of total (free plus bound) local concentration of sirolimus in the tissue (pre-
sented as µg drug per g of tissue) at 10 min (a), 1 hour (b), 4 hours (c) and 1 day (d) after stent implantation.
The results are shown for the uncoupled model and for luminal diameter expansions of 0−30% for the coupled
model in a radial section between the middle struts.
30
Fig. 7. Spatial variation of sirolimus at five different time points (t = 10 min , t = 1 hour, t = 4 hours, t =
24 hours and t = 7 days) for the 0 % (left) and 30 % (right) expansion cases. For each time point the same
colour scale is used for the 0 % and 30 % expansion cases. The maximum values of total local concentration of
sirolimus chosen for each time point are presented as µg drug per g of tissue and they are the following: at t =
10 min, max = 2722.67 µg drug/g tissue; at t = 1 h, max = 1102.44 µg drug/g tissue; at t = 4 h, max = 795.74
µg drug/g tissue; at t = 24 h, max = 283.79 µg drug/g tissue and; at t = 7 d, max = 89.76 µg drug/g tissue. A
comparison between spatial distribution in the tissue of sirolimus and paclitaxel for each expansion case and the
corresponding tables with the maximum values at each time point may be found in the supplementary material.
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Fig. 8. Spatially varying profiles of free local concentration of sirolimus in the tissue (presented as µg drug per
g of tissue) at 10 min (a), 1 hour (b), 4 hours (c) and 1 day (d) after stent implantation. The results are shown
for the uncoupled model and for luminal diameter expansions of 0 − 30% for the coupled model in a radial
section between the middle struts.
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Fig. 9. Spatially varying profiles of local bound concentration of sirolimus in the tissue at 10 min (a), 1 hour
(b), 4 hours (c) and 1 day (d) after stent implantation. The results are shown for the uncoupled model and for
luminal diameter expansions of 0− 30% for the coupled model in a radial section between the middle struts.
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Fig. 10. Spatially varying profiles of binding site % saturation in the tissue at 10 min (a), 1 hour (b), 4 hours (c)
and 1 day (d) after stent implantation, calculated as bibmax · 100. The results are shown for the uncoupled model
and for luminal diameter expansions of 0− 30% for the coupled model in a radial section between the middle
struts.
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normalised media thickness normalised media thickness
Fig. 11. Radial (a) and longitudinal (b) diffusion coefficients variation of sirolimus in the media layer of the
arterial wall. The results are shown for the uncoupled model and for luminal diameter expansions of 0 − 30%
for the coupled model. In both subfigures the radial line is drawn between the middle struts.
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normalised media thickness normalised media thickness
Fig. 12. (a) Radial component of flow in the media. (b) Radial Peclet number variation for sirolimus in the media
layer of the arterial wall. The results are shown for the uncoupled model and for luminal diameter expansions
of 0− 30% for the coupled model. In both subfigures the radial line is drawn between the middle struts.
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